Interest Rate Environment and Funding for Biotech: As a clinical-stage biopharmaceutical company, Aligos Therapeutics relies heavily on funding for research and development. Higher interest rates, influenced by FOMC minutes and CPI data, increase the cost of capital, potentially making it more challenging to secure financing for clinical trials and extend its cash runway.

Regulatory Approval Landscape for Novel Therapies: Aligos's future success is highly dependent on positive clinical trial outcomes and subsequent regulatory approvals from bodies like the FDA. Any tightening of regulatory criteria or delays in the approval process for their therapies targeting liver and viral diseases could significantly impact the company's valuation and stock performance.

Competition and Pipeline Progress in Liver and Viral Diseases: The biopharmaceutical sector, particularly in therapeutic areas such as chronic Hepatitis B and MASH, is highly competitive. The advancement and success of Aligos's pipeline candidates, including pevifoscorvir sodium for HBV and ALG-055009 for MASH, relative to existing treatments and competitor developments, will be a critical determinant of investor sentiment and stock growth.